
Opinion|Videos|June 9, 2025
Closing Thoughts About IgA Nephropathy Treatment
Panelists discuss how the management of immunoglobulin A (IgA) nephropathy is undergoing a transformative shift from symptom control to targeted disease modification, with emerging therapies offering new hope for patients while requiring thoughtful integration into clinical practice and health care systems.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
2
Hereditary Ovarian Cancer Genes Found Beyond Traditionally High-Risk Groups
3
New TROP2-Targeted ADC Shows Promise in TNBC: Erika Hamilton, MD
4
Medicaid Expansion Associated With Lower Mortality in NSCLC
5














































